Raise standards for preclinical cancer research

The effect of lorcainide on arrhythmias and survival in patients with acute myocardial infarction

Reboxetine for acute treatment of major depression

Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy

Dissemination and publication of research findings

Neuraminidase inhibitors--the story behind the Cochrane review

From optimism to disillusion about commitment to transparency in the medico-industrial complex

Comparison of Registered and Published Primary Outcomes in Randomized Controlled Trials

Compliance with mandatory reporting of clinical trial results on ClinicalTrials.gov

新薬の治験の際には結果は医学界の皆のために公開されるべきです。しかし否定的だったり結論が出ないという結果はわずかな例外を除いて報告されずじまいとなり、医師や研究者は闇に取りのこされます。この情熱的なトークでベン・ゴールドエイカーは、これらの否定的なデータが公開されなかった例が、いかに危険で判断を誤らせるものかを説明します。

Ben Goldacre: ベン・ゴールドエイカー: 医者も知らない薬の秘密

ベン・ゴールドエイカー: 医者も知らない薬の秘密

A study shows only 1 in 5 trials reported results within a year, highlighting a significant gap in medicine's evidence base.

Despite laws to ensure clinical trial transparency, a staggering 80% of studies flout reporting rules, undermining medical trust.

The stark discrepancy between positive and negative study outcomes published magnifies a bias, misguiding medical professionals.